Ceritinib/Ceritinib (Ceritinib) Which company's R&D and production background introduction

Ceritinib, trade name: Zykadia, is a targeted drug used to treat ALK-positive non-small cell lung cancer (NSCLC). The drug is developed and produced by the Swiss pharmaceutical company Novartis (Novartis). Novartis was founded in 1996 by the merger of Ciba-Geigy and Sandoz and is headquartered in Basel, Switzerland. Novartis sells its products in more than 155 countries and regions around the world and is committed to improving patients' quality of life through innovative medicines.

Ceritinib was approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of ALK -positive metastatic non-small cell lung cancer. The development of this drug is based on Novartis' deep accumulation in the field of oncology, especially its research on ALK inhibitors. Ceritinib, as a second-generation ALK inhibitor, has high selectivity and potency and can effectively inhibit the growth of tumors caused by ALK mutations.

In the Chinese market, ceritinib is produced and sold by Novartis. According to an announcement on December 28, 2020, Novartis announced that ceritinib has been approved in China for the treatment of ALK-positive non-small cell lung cancer. The launch of this drug provides a new treatment option for Chinese patients, especially those with ALK mutation-positive non-small cell lung cancer.

In short, ceritinib is a targeted drug developed and produced by the Swiss pharmaceutical company Novartis. It is mainly used to treat ALK positive non-small cell lung cancer. The launch of this drug provides patients with new treatment options and reflects Novartis' continued innovation and commitment in the field of oncology.

Reference materials:https://www.drugs.com/